Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Protegrin development candidate selected by IntraBiotics

Nov. 26, 1996

Human brain-derived protein kinase offered for licensing

Nov. 26, 1996

Interim clinical results with Ansan's cancer product

Nov. 22, 1996

New target for drug-resistant tumors identified

Nov. 22, 1996

Mercian discloses novel mitomycin

Nov. 22, 1996

Antitumor lactam isolated by Japanese researchers

Nov. 22, 1996

Vion Pharmaceuticals expands pivotal trials of new cancer treatment

Nov. 21, 1996

Taxotere approved in three additional markets

Nov. 21, 1996

Thalidomide clinical trials in brain cancer expanded

Nov. 21, 1996

Angiogenesis-inhibitory activity reported for spironolactone

Nov. 21, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....
BIO 2026: Alternatives to funding orphan drugs
BioWorld
At the BIO International Convention, nonprofit and for-profit companies discussed ways to fund orphan drug development, especially for ultra-rare diseases where...
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...